Geoffrey M. Parker - Net Worth and Insider Trading

Geoffrey M. Parker Net Worth

The estimated net worth of Geoffrey M. Parker is at least $10 Million dollars as of 2023-09-23. Geoffrey M. Parker is the Director of ChemoCentryx Inc and owns about 129,603 shares of ChemoCentryx Inc (CCXI) stock worth over $7 Million. Geoffrey M. Parker is the Director of Perrigo Co PLC and owns about 47,084 shares of Perrigo Co PLC (PRGO) stock worth over $2 Million. Geoffrey M. Parker is also the Executive Vice President & CFO of Anacor Pharmaceuticals Inc and owns about 104,840 shares of Anacor Pharmaceuticals Inc (ANAC) stock worth over $1 Million. Besides these, Geoffrey M. Parker also holds Better Therapeutics Inc (BTTX) , Sunesis Pharmaceuticals Inc (SNSS) , Tricida Inc (TCDAQ) . Details can be seen in Geoffrey M. Parker's Latest Holdings Summary section.

Transaction Summary of Geoffrey M. Parker

Geoffrey M. Parker Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Geoffrey M. Parker owns 8 companies in total, including Tricida Inc (TCDAQ) , ChemoCentryx Inc (CCXI) , and Perrigo Co PLC (PRGO) among others .

Click here to see the complete history of Geoffrey M. Parker’s form 4 insider trades.

Insider Ownership Summary of Geoffrey M. Parker

Ticker	Comapny	Transaction Date	Type of Owner
TCDAQ	Tricida Inc	2018-06-27	Chief Fin. Officer and Sr. VP
CCXI	ChemoCentryx Inc	2012-02-08	director
PRGO	Perrigo Co PLC	2016-11-07	director
SNSS	Sunesis Pharmaceuticals Inc	2017-05-31	director
ANAC	Anacor Pharmaceuticals Inc	2015-03-23	Executive Vice President & CFO
VIRX	Viracta Therapeutics Inc	2016-03-23	director
BTTX	Better Therapeutics Inc	2021-10-28	director
MCADU	Mountain Crest Acquisition Corp II	2021-10-28	director

Geoffrey M. Parker Latest Holdings Summary

Geoffrey M. Parker currently owns a total of 6 stocks. Among these stocks, Geoffrey M. Parker owns 129,603 shares of ChemoCentryx Inc (CCXI) as of March 5, 2021, with a value of $7 Million and a weighting of 69.73%. Geoffrey M. Parker owns 47,084 shares of Perrigo Co PLC (PRGO) as of June 13, 2023, with a value of $2 Million and a weighting of 15.71%. Geoffrey M. Parker also owns 104,840 shares of Anacor Pharmaceuticals Inc (ANAC) as of March 23, 2015, with a value of $1 Million and a weighting of 10.65%. The other 3 stocks Better Therapeutics Inc (BTTX) , Sunesis Pharmaceuticals Inc (SNSS) , Tricida Inc (TCDAQ) have a combined weighting of 3.91% among all his current holdings.

Latest Holdings of Geoffrey M. Parker

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CCXI	ChemoCentryx Inc	2021-03-05	129,603	51.99	6,738,060
PRGO	Perrigo Co PLC	2023-06-13	47,084	32.25	1,518,459
ANAC	Anacor Pharmaceuticals Inc	2015-03-23	104,840	9.82	1,029,529
BTTX	Better Therapeutics Inc	2023-07-27	1,081,388	0.34	367,564
SNSS	Sunesis Pharmaceuticals Inc	2016-12-09	1,878	5.32	9,991
TCDAQ	Tricida Inc	2020-12-10	250,837	0.00	3

Holding Weightings of Geoffrey M. Parker

Geoffrey M. Parker Form 4 Trading Tracker

According to the SEC Form 4 filings, Geoffrey M. Parker has made a total of 3 transactions in ChemoCentryx Inc (CCXI) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in ChemoCentryx Inc is the sale of 31,910 shares on March 5, 2021, which brought Geoffrey M. Parker around $2 Million.

According to the SEC Form 4 filings, Geoffrey M. Parker has made a total of 5 transactions in Perrigo Co PLC (PRGO) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Perrigo Co PLC is the acquisition of 10,000 shares on June 13, 2023, which cost Geoffrey M. Parker around $330,600.

According to the SEC Form 4 filings, Geoffrey M. Parker has made a total of 0 transactions in Anacor Pharmaceuticals Inc (ANAC) over the past 5 years. The most-recent trade in Anacor Pharmaceuticals Inc is the acquisition of 3,000 shares on March 23, 2015, which cost Geoffrey M. Parker around $157,290.

More details on Geoffrey M. Parker's insider transactions can be found in the Insider Trading History of Geoffrey M. Parker table.

Insider Trading History of Geoffrey M. Parker

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Geoffrey M. Parker Trading Performance

GuruFocus tracks the stock performance after each of Geoffrey M. Parker's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Geoffrey M. Parker is 8.67%. GuruFocus also compares Geoffrey M. Parker's trading performance to market benchmark return within the same time period. The performance of stocks bought by Geoffrey M. Parker within 3 months outperforms 17 times out of 38 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Geoffrey M. Parker's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Geoffrey M. Parker

Average Relative Return

40.82%

Average relative return per transaction

Outperforming Transactions

54%

19 out of 35 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Relative Return(%)	2.07	8.67	17.97	40.82	41	15.76
Relative Return to S&P 500(%)	1.87	6.09	14.13	28.16	28.28	3.33

Geoffrey M. Parker Ownership Network

Ownership Network List of Geoffrey M. Parker

No Data

Ownership Network Relation of Geoffrey M. Parker

Geoffrey M. Parker Owned Company Details

What does Tricida Inc do?

Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.

Who are the key executives at Tricida Inc?

Geoffrey M. Parker is the Chief Fin. Officer and Sr. VP of Tricida Inc. Other key executives at Tricida Inc include 10 percent owner & other: *possible member of 10% group Sibling Capital Ventures Iii Llc , 10 percent owner & other: *possible member of 10% group Sibling Capital Fund Ii-c L.p. , and 10 percent owner & other: *possible member of 10% group Brian M. Isern .

Tricida Inc (TCDAQ) Insider Trades Summary

Over the past 18 months, Geoffrey M. Parker made no insider transaction in Tricida Inc (TCDAQ). Other recent insider transactions involving Tricida Inc (TCDAQ) include a net sale of 1,922,883 shares made by Venrock Healthcare Capital Partners Ii, L.p. , a net sale of 331,038 shares made by Sibling Capital Fund Ii-a L.p. , and a net sale of 159,463 shares made by Robert J Alpern .

In summary, during the past 3 months, insiders sold 0 shares of Tricida Inc (TCDAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 27,863,935 shares of Tricida Inc (TCDAQ) were sold and 4,528,657 shares were bought by its insiders, resulting in a net sale of 23,335,278 shares.

Tricida Inc (TCDAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tricida Inc Insider Transactions

No Available Data

What does ChemoCentryx Inc do?

ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Who are the key executives at ChemoCentryx Inc?

Geoffrey M. Parker is the director of ChemoCentryx Inc. Other key executives at ChemoCentryx Inc include SVP & Finance & Acctg Officer Yi Ching Yau , EVP & Chief Operating Officer Tausif Butt , and 10 percent owner Vifor Pharma Ltd. .

ChemoCentryx Inc (CCXI) Insider Trades Summary

Over the past 18 months, Geoffrey M. Parker made no insider transaction in ChemoCentryx Inc (CCXI). Other recent insider transactions involving ChemoCentryx Inc (CCXI) include a net sale of 66,196 shares made by Susan M Kanaya , a net sale of 130,000 shares made by Thomas J. Schall , and a net sale of 3,863 shares made by James L Tyree .

In summary, during the past 3 months, insiders sold 0 shares of ChemoCentryx Inc (CCXI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 200,059 shares of ChemoCentryx Inc (CCXI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 200,059 shares.

ChemoCentryx Inc (CCXI)'s detailed insider trading history can be found in Insider Trading Tracker table.

ChemoCentryx Inc Insider Transactions

No Available Data

What does Perrigo Co PLC do?

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Who are the key executives at Perrigo Co PLC?

Geoffrey M. Parker is the director of Perrigo Co PLC. Other key executives at Perrigo Co PLC include director & CEO Patrick Lockwood-taylor , EVP & Chief Scientific Officer Alison Ives , and EVP & General Counsel Kyle Hanson .

Perrigo Co PLC (PRGO) Insider Trades Summary

Over the past 18 months, Geoffrey M. Parker made 2 insider transaction in Perrigo Co PLC (PRGO) with a net purchase of 15,000. Other recent insider transactions involving Perrigo Co PLC (PRGO) include a net sale of 197,646 shares made by Murray S Kessler , a net sale of 9,000 shares made by Dillard James E Iii , and a net sale of 4,500 shares made by Ronald Craig Janish .

In summary, during the past 3 months, insiders sold 0 shares of Perrigo Co PLC (PRGO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 217,237 shares of Perrigo Co PLC (PRGO) were sold and 17,900 shares were bought by its insiders, resulting in a net sale of 199,337 shares.

Perrigo Co PLC (PRGO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Perrigo Co PLC Insider Transactions

No Available Data

What does Sunesis Pharmaceuticals Inc do?

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Who are the key executives at Sunesis Pharmaceuticals Inc?

Geoffrey M. Parker is the director of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks William P. Quinn .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Anacor Pharmaceuticals Inc do?

Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.

Who are the key executives at Anacor Pharmaceuticals Inc?

Geoffrey M. Parker is the Executive Vice President & CFO of Anacor Pharmaceuticals Inc. Other key executives at Anacor Pharmaceuticals Inc include Executive VP and CFO Graeme Bell , EVP and General Counsel Ryan T Sullivan , and director & President and CEO Paul L Berns .

Anacor Pharmaceuticals Inc (ANAC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Anacor Pharmaceuticals Inc (ANAC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Anacor Pharmaceuticals Inc (ANAC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Anacor Pharmaceuticals Inc (ANAC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Anacor Pharmaceuticals Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Who are the key executives at Viracta Therapeutics Inc?

Geoffrey M. Parker is the director of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Medical Officer Darrel P. Cohen , director & President and CEO Mark Rothera , and Chief Executive Officer Daniel R. Chevallard .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Geoffrey M. Parker made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 21,529 shares made by Daniel R. Chevallard , a net sale of 8,616 shares made by Lisa Rojkjaer , and a net sale of 26,541 shares made by Ivor Royston .

In summary, during the past 3 months, insiders sold 3,512 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 3,512 shares. During the past 18 months, 56,686 shares of Viracta Therapeutics Inc (VIRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 56,686 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

What does Better Therapeutics Inc do?

Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.

Who are the key executives at Better Therapeutics Inc?

Geoffrey M. Parker is the director of Better Therapeutics Inc. Other key executives at Better Therapeutics Inc include 10 percent owner Georgianna Maule-ffinch 2015 Trust , director & See Remarks Frank Karbe , and director & 10 percent owner & See Remarks David P Perry .

Better Therapeutics Inc (BTTX) Insider Trades Summary

Over the past 18 months, Geoffrey M. Parker made 4 insider transaction in Better Therapeutics Inc (BTTX) with a net purchase of 1,028,055. Other recent insider transactions involving Better Therapeutics Inc (BTTX) include a net purchase of 657,040 shares made by Andrew J. Armanino , a net purchase of 6,252,742 shares made by David P Perry , and a net purchase of 429,429 shares made by Frank Karbe .

In summary, during the past 3 months, insiders sold 0 shares of Better Therapeutics Inc (BTTX) in total and bought 2,418,138 shares, with a net purchase of 2,418,138 shares. During the past 18 months, 0 shares of Better Therapeutics Inc (BTTX) were sold and 8,514,200 shares were bought by its insiders, resulting in a net purchase of 8,514,200 shares.

Better Therapeutics Inc (BTTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Better Therapeutics Inc Insider Transactions

No Available Data

What does Mountain Crest Acquisition Corp II do?

Mountain Crest Acquisition Corp II is a blank check company.

Who are the key executives at Mountain Crest Acquisition Corp II?

Geoffrey M. Parker is the director of Mountain Crest Acquisition Corp II. Other key executives at Mountain Crest Acquisition Corp II include director & See Remarks Frank Karbe , director & 10 percent owner & See Remarks David P Perry , and director & 10 percent owner & Chief Executive Officer Kevin J Appelbaum .

Mountain Crest Acquisition Corp II (MCADU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Mountain Crest Acquisition Corp II (MCADU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Mountain Crest Acquisition Corp II (MCADU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Mountain Crest Acquisition Corp II (MCADU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mountain Crest Acquisition Corp II Insider Transactions

No Available Data

Geoffrey M. Parker Mailing Address

Above is the net worth, insider trading, and ownership report for Geoffrey M. Parker. You might contact Geoffrey M. Parker via mailing address: 15 Riordan Place, Menlo Park Ca 94025.

Discussions on Geoffrey M. Parker

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.